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Abstract 
The success of mechanism-based drug discovery depends on the definition of the 
drug target. This definition becomes even more important as we try to link drug 
response to genetic variation, understand stratified clinical efficacy and safety, 
rationalize the differences between drugs in the same therapeutic class and predict 
drug utility in patient subgroups. However, drug targets are often poorly defined in 
the literature, both for launched drugs and for potential therapeutic agents in 
discovery and development. Here, we present an updated comprehensive map of 
molecular targets of approved drugs. We curate a total of 893 human and pathogen-
derived biomolecules through which 1,578 US FDA-approved drugs act. These 
biomolecules include 667 human-genome-derived proteins targeted by drugs for 
human disease. Analysis of these drug targets indicates the continued dominance of 
privileged target families across disease areas, but also the growth of novel first-in-
class mechanisms, particularly in oncology. We explore the relationships between 
bioactivity class and clinical success, as well as the presence of orthologues 
between human and animal models and between pathogen and human genomes. 
Through the collaboration of three independent teams, we highlight some of the 
ongoing challenges in accurately defining the targets of molecular therapeutics and 
present conventions for deconvoluting the complexities of molecular pharmacology 
and drug efficacy. 
 
Key points 
 The definition of a drug target is crucial to the success of mechanism-based 
drug discovery. It is also increasingly important for efforts to link drug 
response to genetic variation, understand stratified clinical efficacy and safety, 
rationalize the differences between drugs in the same therapeutic class and 
predict drug utility in patient subgroups. 
 In this article, we synthesized and built on our previous approaches and 
systematically recompiled and comprehensively annotated the current list of 
drugs approved by the US FDA. We assigned to each drug their respective 
efficacy target or target set from the prescribing information and/or the 
scientific literature. 
 We curated a total of 893 human and pathogen-derived biomolecules through 
which 1,578 FDA-approved drugs act. These include 667 human-genome-
derived proteins targeted by drugs for human disease. 
 We emphasize that even with a well-defined concept of efficacy there are 
challenges in making a clean unambiguous assignment in many cases, 
especially regarding how to treat protein complexes or drugs that bind to a 
number of closely related gene products. 
 We also mapped each drug (and thereby target) to the WHO Anatomical 
Therapeutic Chemical Classification System code as a way of obtaining a 
standard therapeutic indication for them. 
 With this mapping, we explored the footprint of target classes across disease 
areas, investigated the success of privileged target families and compiled a 
list of drug target orthologues for standard model organisms to develop a 
foundation for the deeper understanding of species differences, cross-species 
drug repositioning and applicability of animal models. 
 
Introduction 
James Black famously stated in 2000 that “the best way to discover a new drug is to 
start with an old one” (Ref. 1). Where available, a deep understanding of the 
mechanistic action of targeted drugs continues to inform drug discovery, clinical trials 
and efforts to overcome drug resistance. Thus, maintaining an accurate and up-to-
date map of approved drugs and their efficacy targets — that is, the targets through 
which the drugs exert their therapeutic effect — is an important activity that will guide 
future drug development and innovation. 
Arguably, the first attempt to compile a definitive target list dates from 1996, when 
Drews and Ryser estimated the number of human molecular targets for approved 
small-molecule drugs2,3. From this article and subsequent analyses4,5,6, the 
concept of 'privileged' protein families that have had a consistent and successful 
history of drug discovery began to emerge. In 2006, we published a compendium of 
drug targets7 and identified that the then available US FDA-approved targeted drugs 
acted through 324 mechanistic protein targets. Alongside the well-established 
druggable families, we analysed privileged families and additionally identified a 'long 
tail' of diverse, structurally unrelated protein families with small numbers of members, 
as well as single proteins. 
Several databases now provide data on drug–target interactions, each with different 
scopes and foci. The first was the Therapeutic Targets Database8. DrugBank9, the 
most widely used specialist drug information resource, maps drugs to proteins that 
have been reported to bind to them, and SuperTarget10 is a text-mining-based 
compilation of direct and indirect drug targets. More recently, Rask-Andersen et al.11 
provided an updated view on the status of current drugs and the human targets 
believed to be responsible for their efficacy in their approved indications. 
Additionally, Munos12 has highlighted trends in drug classes and target innovation 
for the past decade, and Agarwal et al.13 have analysed the overlap and uniqueness 
in the drug targets that are being pursued by industry. Finally, the International Union 
of Basic and Clinical Pharmacology and British Pharmacological Society 
(IUPHAR/BPS) Guide to Pharmacology database (see Further information) also 
compiles information on approved drugs, together with affinity and selectivity data, 
and assigns primary targets that are supported by experimental evidence14. 
However, despite the variety of valuable online resources, it is still a challenge to 
retrieve a consistent and comprehensive view of the targets of approved drugs 
(covering both small molecules and biologics) with their associated molecular 
efficacy targets (human and pathogen) organized by therapeutic use. Furthermore, 
although the concept of a target is a natural one for researchers in the field, there are 
substantial operational difficulties in consistently mapping this target concept to 
specific genes and gene products in practice. 
Here, we synthesize and build on our previous approaches7 to systematically 
recompile and comprehensively annotate the current list of FDA-approved drugs. We 
assign to each drug their respective efficacy target or target set from the prescribing 
information and/or the scientific literature. We emphasize that even with a well-
defined concept of efficacy there are challenges in making a clean unambiguous 
assignment in many cases, especially regarding how to treat protein complexes or 
drugs that bind to a number of closely related gene products. 
We also map each drug (and thereby target) to the WHO Anatomical Therapeutic 
Chemical Classification System code (ATC code; see Further information) as a way 
of obtaining a standard therapeutic indication for them. The ATC hierarchy 
consistently classifies drugs according to the organ or system on which they act, and 
their therapeutic effects, pharmacological actions and chemical class. With this 
mapping, we explore the footprint of target classes across disease areas and 
investigate the success of privileged target families given the investment in discovery 
effort. We also compile a list of drug target orthologues for standard model 
organisms to develop a foundation for the deeper understanding of species 
differences, cross-species drug repositioning and applicability of animal model 
systems. 
Complexities in defining efficacy targets 
Defining the set of mechanistic drug targets requires unambiguous evidence of the 
therapeutic action of drugs through clear biomolecular partners. In reality, this 
association is not always straightforward. Although in many cases it is possible to 
annotate a widely accepted and unambiguous target, for other drugs there is often 
disagreement or changes in understanding over time, which is then reflected in 
differences between primary sources. To address this challenge, we have 
reassigned efficacy targets afresh from the primary literature an d prescribing 
information and combined annotations made by three independent teams of curators 
at the European Molecular Biology Laboratory-European Bioinformatics Institute 
(EMBL–EBI) ChEMBL database, the University of New Mexico DrugCentral 
database15 and The Institute of Cancer Research canSAR knowledge base16 (see 
Further information). We defined a simple, consistent set of guidelines to help us 
assign therapeutic targets (the full set of guidelines is shown in Box 2). Overall, we 
did not assign targets solely on the basis of reported biochemical and pharmacology 
data, which are now widely available17. Although there may be evidence for drugs 
binding with moderate or even high affinity to multiple additional targets, we do not 
consider these as efficacy targets unless there is evidence for their role in the 
therapeutic effect of the drug. 
For example, antipsychotics are considered to exert their effect largely by acting as 
antagonists of the dopamine D2 receptor (encoded by DRD2) and sometimes as 
antagonists or inverse agonists of the 5-hydroxytryptamine (5-HT; also known as 
serotonin) 2A receptor (encoded by HTR2A)18,19. However, antipsychotics also 
bind with nanomolar affinity to other 5-HT receptor subtypes, as well as adrenergic, 
muscarinic and histamine receptors (Supplementary information S1 (box)). Despite 
much speculation and investigation, however, the contribution of these additional 
targets to the therapeutic effect of antipsychotics has not yet been demonstrated. For 
example, the therapeutic effect of aripiprazole, a “dopamine–serotonin system 
stabilizer” (Ref. 20), has been attributed to it acting as a partial agonist of D2 and 5-
HT1A receptors and an antagonist of the 5-HT2A receptor21, although it also 
interacts with other proteins. However, the dopamine stabilizer (–)-OSU6162 
appears to occupy a subpopulation of striatal D2/D3 receptors with moderate 
(micromolar) affinity22, which suggests that a specific interplay between, for 
example, D2 receptor occupancy and tissue specificity (striate nucleus) may be more 
therapeutically relevant. Consequently, targets other than D2 and 5-HT2A receptors 
have not been annotated as efficacy targets of antipsychotic drugs. The fact that a 
drug has high affinity to an alternative target, or that different drugs from the same 
class have differentiated target binding profiles, can be important in developing next-
generation agents. 
Another challenge is how to assign targets to drugs reported to have broad 
mechanistic effects; examples of such drugs include muscarinic receptor 
antagonists, voltage-gated potassium channel blockers and broad-spectrum β-
lactam antibiotics. For these drugs, one possible solution would be to list the 5 
muscarinic receptors for the first case, the 4 α-subunits that may form voltage-gated 
potassium channels for the second case and, for the third case, to pick all the 
penicillin-binding proteins (PBPs) from all the bacterial species against which the 
drug is effective. However, in the case of human targets, a more restricted subset 
based on selectivity data or expression data could also potentially be chosen. For 
the pathogen targets, a representative pathogen species could be chosen and only 
the biomolecules or cellular components of that species could be assigned as drug 
targets. In making our assignments, we have identified such subsets among the 
human targets for which sufficient information was available to do so. For targets for 
which there was inadequate evidence to determine which subunits or family 
members play a key part, we listed all possible proteins. For example, all anti-
muscarinic agents indicated to treat bronchospasms have muscarinic acetylcholine 
receptor M3 (encoded by CHRM3) assigned as their efficacy target because this 
muscarinic receptor has the highest expression levels in the airways and is 
responsible for bronchoconstriction23,24. However, there is evidence to indicate that 
M1 and M2 receptors cannot be definitively excluded; for example, M1 receptors are 
responsible for bronchoconstriction in humans25, whereas tissue expression data 
seem to indicate that M2 receptors might be equally involved24. 
For broad-spectrum antibacterials, Escherichia coli was selected as the 
representative species in ChEMBL. Thus, all broad-spectrum β-lactam antibiotics 
were linked to the seven PBPs from E. coli, even though it is clear that not all PBPs 
are targets for all β-lactams in all species26. In DrugCentral, however, susceptible 
pathogen species were assigned as targets based on antibacterial data reported as 
minimum inhibitory concentrations against well-defined pathogens. For example, 
finafloxacin, a fluoroquinolone approved for treating otitis caused by Pseudomonas 
aeruginosa and/or Staphylococcus aureus, was annotated as targeting both species. 
With minimum inhibitory concentration and species data available, a microbiologist 
can compare antibiotic potencies and susceptibilities, which are both important 
aspects of antibiotic efficacy. This strategy is complementary to the ChEMBL 
approach of annotating molecular targets; for example, all fluoroquinolones are 
annotated as E. coli DNA gyrase inhibitors. The DrugCentral approach focuses on 
the microorganism rather than the bacterial protein target because there is no clear 
evidence that the antibacterial would be efficacious in other species. Furthermore, 
bacteria have topical specificity in that some prefer the colon (for example, E. coli), 
whereas some prefer the nasopharyngeal sinus cavities, lung, kidney or skin. 
Antibiotics are prescribed differently for different infections. This difference makes 
target assignment even more complicated because particular antibiotics may be 
taken up via active transport into a certain tissue (where the infection is), whereas 
others may not. In addition, infections cause tissues to respond differently. For 
example, bacterial meningitis makes the blood–brain barrier leaky, enabling the use 
of antibiotics that otherwise do not cross this barrier but are effective in such 
infections. Such pathology-related phenomena are even more difficult to account for 
at a molecular level. 
Oncology is a therapeutic area that further illustrates the challenges in defining 
efficacy targets. The FDA-approved drugs assigned to ATC categories L01 
(antineoplastics) and L02 (endocrine therapies) can be broadly divided into three 
groups. The first group are cytotoxic agents that target human DNA and/or RNA, 
such as platinum compounds. The second group are cytotoxic agents that act at 
least partially through protein targets, such as DNA polymerase, DNA topoisomerase 
and the proteasome. Finally, drugs in the third group are those that are typically 
considered to be targeted therapeutics, such as kinase inhibitors. However, the 
assignment of a drug to the third group rather than the second group is complicated 
by the spectrum of targeting observed. Topoisomerase inhibitors, for example, are 
selective for their targets but are highly toxic. Conversely, some kinase inhibitors 
inhibit a wide range of normally functioning kinases and their associated pathways, 
and adverse reactions to these drugs have been reported in the clinic. A further 
challenge in the assignment of efficacy targets to cancer drugs is the rapidly growing 
number of kinase inhibitors (37 approved small-molecule protein kinase inhibitors 
worldwide as of June 2016). The original clinical hypothesis may be based on the 
alteration of a specific gene (for example, epidermal growth factor receptor (EGFR)), 
but the resultant launched drug may inhibit a broad range of kinase targets, most of 
which function outside the deregulated pathway — although kinase signalling 
pathways are largely interconnected in cancer. For example, vandetanib, which was 
approved for the treatment of metastatic medullary thyroid cancer27, inhibits the 
kinase product of the oncogene RET, which is mutated in many patients with 
medullary thyroid cancer28. Vandetanib also inhibits other kinases with 
interconnecting pathways, such as EGFR and vascular endothelial growth factor 
receptor (VEGFR) pathways. Indeed, it is common for the prescribing information to 
list a large number of targets in the section describing the mechanism of action of the 
drug, and certainty about the importance of a single target can usually only be 
obtained when the drug is approved in conjunction with a companion diagnostic test 
(see Further information). However, in contrast to the situation with D2 receptor 
antagonists described above, the kinases listed as binding a drug in the prescribing 
information often act on interlinked pathways; thus, we have mechanistic reasons to 
suspect their involvement in the efficacy of the drug. Therefore, we attempted to 
include all proteins that are likely to contribute to the observed efficacy of a drug as 
part of our drug target list, and this list will change as our understanding of drug 
action improves. 
Using these guidelines, the final assignment still requires substantial curation effort. 
For example, for dronedarone, an anti-arrhythmic drug approved in 2009, the FDA 
label (see Further information) states that it has anti-arrhythmic properties belonging 
to all four Vaughan–Williams classes, and that its mechanism of action is “unknown”. 
This statement implies that at a molecular level, it may have the capacity to modulate 
sodium channels (class I), β-adrenergic receptors (class II), voltage-gated potassium 
channels (class III) and L-type calcium channels (class IV)23. Recently, blockade of 
the If current (funny current) via HCN (hyperpolarization-activated cyclic nucleotide-
gated) channels — of which there are four subtypes, with HCN4 being the form most 
highly expressed in the sinoatrial node29 — was identified as the likely mechanism 
for the bradycardic effect of dronedarone30, rather than modulating L-type calcium 
channels or β-adrenergic receptors. Notably, ivabradine, a recently approved cardiac 
drug, also blocks If currents via HCN channels29,31. However, the dronedarone 
study30 did not rule out a role for sodium channels or voltage-gated potassium 
channels in the overall efficacy of the drug, but focused purely on its bradycardic 
effect. Other studies have further suggested that the inhibition of inward-rectifier 
potassium channels (in particular Kir2.1 (Refs 32,33)) may contribute to the 
antifibrillatory efficacy of dronedarone. A recent review makes it clear that 
dronedarone has many anti-arrhythmic effects and has a complex mechanism of 
action that probably involves many different target classes to a greater or lesser 
extent34. 
This complexity is reflected by the diversity of annotations included in other 
databases for this drug. For example, Rask-Andersen et al.11 assigned one voltage-
gated potassium channel (Kv11.1; encoded by KCNH2) and two adrenergic 
receptors as targets for dronedarone, whereas the Therapeutic Targets Database 
lists only Kv1.5 (another voltage-gated potassium channel) as a target. DrugBank 
lists a total of 18 proteins (adrenergic receptors, sodium and potassium channels 
and L-type calcium channels) for dronedarone, but all flagged with 'pharmacological 
action unknown' because, for their curator, their therapeutic role is uncertain. Finally, 
the IUPHAR/BPS Guide to Pharmacology database does not include any primary 
target information (or binding affinity data) for dronedarone, although it does describe 
its mechanism as involving adrenergic receptors and sodium, potassium and calcium 
channels35. In January 2016, none of these resources annotated HCN channels as 
a dronedarone target, even though this specific information was published several 
years ago and at least one follow-up review dedicated to dronedarone agrees that 
HCN channel blockade may be an important mechanism of action34. 
The complex case of dronedarone highlights that our annotations are only a 
snapshot that represents current knowledge. We will continue to curate and update 
our assignments in the ChEMBL, DrugCentral and canSAR databases as more 
experiments are performed and knowledge of drug mechanisms increases. Such 
complexity is also at the heart of the concept of network pharmacology — the 
proposal that often several simultaneous distinct points of intervention are required 
for drug action. It remains to be seen in practice what proportion of drugs absolutely 
require binding to multiple targets for their efficacy. 
Drugs, targets and therapeutic areas 
Target annotations were combined from the ChEMBL, DrugCentral and canSAR 
databases to provide a unified set of drug efficacy targets, provided in 
Supplementary information S2 (table). Using this approach, we identified 667 unique 
human protein efficacy targets and 189 pathogen protein efficacy targets (Table 1). 
Using the ChEMBL hierarchical target classification system17, we then examined 
how the human protein targets distribute into homologous families and identified the 
most enriched ones. Rhodopsin-like G protein-coupled receptors (GPCRs; also 
known as 7TM1), ion channels, protein kinases and nuclear hormone receptors were 
considered to be privileged families given that they alone account for 44% of all 
human protein targets (GPCRs: 12%; ion channels: 19%; kinases: 10%; and nuclear 
receptors: 3% (Fig. 1a)). Moreover, owing to the variable number of approved drugs 
per target, these privileged families are responsible for the therapeutic effect of 70% 
of small-molecule drugs (GPCRs: 33%; ion channels: 18%; kinases: 3%; and nuclear 
receptors: 16% (Fig. 1a)). 
There is a large difference between the drug and target fractions for protein kinases 
because of the broad polypharmacology typical of small-molecule kinase inhibitors, 
whereas the opposite is seen for nuclear receptors. The area of directed protein 
kinase inhibitors was highlighted in our original 2006 publication as an emerging 
target class7, and this trend has clearly continued. The remaining human protein 
efficacy targets are mostly unrelated enzymes. In the case of biologics, secreted or 
surface antigen proteins are the most important target class. This result is as 
expected given the highly restricted compartmental distribution of high-molecular-
mass drugs within the body. 
The number of drugs per target and the number of targets per drug are noteworthy in 
our analysis. By simple averaging, we obtain the figure of two drugs per target. 
However, this result is an oversimplification of complex pharmacology. Some targets 
have provided a rich ground for selective drugs, such as the glucocorticoid receptor 
(which has 61 approved drugs), whereas others fall into the opposite category, such 
as kinase inhibitors, for which few drugs act on many targets, thus contributing to the 
overall pharmacological response to those drugs (Supplementary information S3 
(figure)). Another key developing trend is monoclonal antibody therapies, which are 
typically highly specific to a single gene product. This contrasts with small-molecule 
drugs, for which the interaction with multiple targets (polypharmacology) is more 
common. 
Kinase inhibitors provide some of the best-known examples of polypharmacology 
because their bioactivity is routinely profiled against many kinases (and other 
targets) during the drug discovery and development process. This profiling was 
made possible by the introduction of high-throughput (in vitro) assay technologies. 
However, for most drugs, which were approved before 1990, this type of target 
profiling was not systematic; thus, our ability to understand polypharmacology both 
within and outside target families is a more recent endeavour. 
The highly biased distribution in successfully 'drugged' protein families is also 
reflected in the biased distribution of bioactivity data from the ChEMBL database 
when examining the data at the target class level (Fig. 1b). ChEMBL is an open-
access, large-scale bioactivity database containing manually extracted information 
from the medicinal chemistry literature together with data from United States 
Adopted Name (USAN) applications. Consequently, ChEMBL provides an unbiased 
reflection of small-molecule compounds at the lead optimization phase of drug 
discovery17. The protein-family-based organization of the data enables detailed 
examination of attrition during clinical development at a target family level 
(specifically, potent leads can be identified, but these may then fail in clinical 
development). Pooling the data by family enables a more robust statistical analysis 
and reduces the impact of specific targets on the analysis. As shown in Fig. 1b, it is 
clear that the discovery-phase investment in rhodopsin-like GPCRs has, at least until 
now, consistently paid off, because the fraction of approved drugs is slightly higher 
than the fraction of compounds in ChEMBL targeted to members of this family. The 
same relative enrichment (or survival) through clinical development is found for 
nuclear receptors, voltage-gated ion channels (VGICs), various reductases, 
electrochemical transporters and ligand-gated ion channels (LGICs). Curiously, in 
the case of nuclear receptors, no new efficacy target belonging to this family has 
emerged in recent years, although some are currently in trials (Supplementary 
information S4 (figure)). For protein kinases and proteases, the return in investment 
has shown the opposite trend. However, interest in protein kinases as drug targets is 
more recent (data not shown), and many potential kinase-directed drugs are still in 
active clinical development. For the extensively explored and high-attrition families 
— for example, the trypsin-like serine proteases — these data support the possibility 
that, on average, the family has low inherent druggability. Other examples from this 
simple data-driven analysis point to specific target-based attrition in some cases; for 
example, more than 40 mitogen-activated protein kinase p38α (also known as 
MAPK14) inhibitors have entered clinical trials, but have typically only progressed to, 
or stalled in, phase II trials. 
To gain insight into drug innovation patterns by disease area, we linked a target to 
cognate drugs and then the drugs to their ATC codes. The number of small-molecule 
and biologic drugs per therapeutic area are shown in Table 2. We then grouped 
drugs per ATC level 3 code according to their worldwide or FDA approval year. As 
shown in Fig. 2, the maturity of the drugs targeting the cardiovascular system 
(category C) or the dermatological system (category D) is clear. By contrast, Fig. 2 
also illustrates the recent innovation in the oncology and immunology areas 
(category L), as well as the recent lack of progress and small number of drugs 
available in the antiparasitic class (category P). A similar analysis at the target family 
level reveals a higher number of recently approved drugs that modulate kinases 
compared with the number of recently approved drugs that act through either nuclear 
receptors or ion channels (Fig. 3). Specifically, 20 protein kinase inhibitors have 
been approved by the FDA since 2011, accounting for 28% of all kinase-modulating 
drugs. This fraction would be even higher if only small molecules were considered in 
the analysis because biologics such as insulin derivatives (mainly approved before 
1990) constitute a substantial portion of the kinase-modulating drugs (although these 
biologics do not bind to the protein kinase catalytic domain, which is typically used to 
define family membership). 
Finally, to investigate the relationship between drugs, target classes and therapeutic 
areas, we again linked a target to cognate drugs and the drugs to their ATC codes, 
then connected drugs that share efficacy targets belonging to the same target class. 
In this way, we can analyse target family or functional class promiscuity across 
diseases or anatomical systems (Fig. 4). For example, if we look at several of the 
previously identified privileged target families — membrane receptors belonging to 
rhodopsin-like GPCRs, VGICs, LGICs and protein kinases — we see that rhodopsin-
like GPCRs are targets for small-molecule drugs across almost every ATC class 
(Fig. 4a), with the exception of antiparasitic products (category P) and hormonal 
systems (category H). By contrast, protein kinases, which represent 13% of the 
protein human efficacy targets assigned to small molecules, only account for 2.4% of 
the small-molecule drugs, almost all of which are antineoplastic and 
immunomodulating agents (category L). This category is also represented when 
linking kinases assigned to biologic drugs, but for this type of drug, kinases seem to 
have an important role in other anatomical systems too. For biologics overall, only a 
small fraction of ATC categories are covered (Fig. 4b). As shown in Fig. 4a, the 
patterns created by ion channels are also distinct. Both VGICs and LGICs cover the 
musculoskeletal system (category M), the nervous system (category N), the 
alimentary tract and metabolism (category A), the respiratory system (category R), 
and the cardiovascular system (category C). The VGIC family also covers the 
dermatological system (category D) and the sensory system (category S). It is 
interesting to speculate that this clustering reflects a deeply rooted evolutionary 
relationship of various signalling and control subsystems of the body, and may 
provide additional guidance and constraints in effective drug repositioning and side-
effect liability. 
Worldwide drug approvals 
Although the analysis presented above is restricted to FDA-approved drugs and 
antimalarials approved in the rest of the world, we have also collated mechanism- of-
action data on an additional set of ∼1,200 drugs from WHO International 
Nonproprietary Names (INN) lists (see Further information) combined with literature 
searches35,36 to select drugs approved by other regulatory agencies. The vast 
majority of these drugs are members of the same chemical classes and share the 
same target (or targets) as an FDA-approved drug. For example, etoricoxib, a 
selective cyclooxygenase 2 (COX2) inhibitor, is approved in more than 80 countries 
but has not currently received FDA approval owing to safety concerns, whereas 
fimasartan, an angiotensin II receptor antagonist, is approved in South Korea only. 
Inclusion of these drugs identified eight additional, novel drug efficacy targets (Table 
3). 
Orthologues in animal models 
Selecting the best model organism to study a particular disease or to validate a novel 
target mechanism involves identifying an induced disease state in a model organism 
with sufficient similarities to human pathology that a reliable prediction of the effects 
in humans may be made on the basis of the effects in the model organism. In 
practice, this is not straightforward. One approach that can be used to select a 
suitable model organism is to take the core human 'pharmacolome' (which we define 
here as the set of gene products that are modulated by current drugs) to compile a 
list of orthologues in typical model organisms. These genes can then be mapped 
back to the respective protein efficacy targets, the efficacy targets to the drugs and 
the drugs to the therapeutic indication (through the ATC code). Thus, from these 
data, one can infer which therapeutic areas are potentially best mimicked by which 
model organism. Figure 5 is a visualization of this information in a single plot (see 
Supplementary information S5 (figure) for a full-sized version). As in Fig. 4, the outer 
ring corresponds to the ATC categories scaled to the number of approved drugs in 
those categories. The inner ring is composed of ATC level 4 categories, which 
indicate the chemical, therapeutic and pharmacological subgroup. A series of 
heatmaps per species is then shown, coloured by how many of the protein efficacy 
targets are conserved for that ATC level 4 category between model organisms. The 
dark blue sections in Homo sapiens or E. coli heatmaps indicate that the drug target 
is a human protein or a bacterial protein. The conservation of efficacy targets is 
always with respect to the drug target species. 
Overall, the vertebrates (dog, pig, rat, mouse and zebrafish) all provide 
comparatively good coverage of the set of human drug targets. In some cases, 
however, the apparent variation is due to the currently incomplete annotation in 
genome annotation and/or orthologue assignment for more recently completed 
genomes. As would be expected, the genomes of Drosophila and Caenorhabditis 
elegans contain fewer orthologues for human disease targets. The differences reflect 
anatomical systems that are substantially different or missing compared with 
humans. However, the degree of conservation varies significantly between the two 
species and between different therapeutic areas. For example, C. elegans retains 
many of the targets that are responsible for the efficacy of dermatological and genito-
urinary drugs, whereas these appear to be absent in Drosophila. When considering 
even simpler unicellular organisms such as yeast or E. coli, generally only targets 
reflecting core essential cellular functions, such as DNA, protein and nucleotide 
synthesis, remain. 
When seeking to identify novel anti-infective targets, it is often proposed that 
absence of the corresponding protein in the host organism (normally humans) is an 
important prerequisite for success, and such constraints are often applied in 
bioinformatics filtering of potential targets. However, it can be seen from Fig. 5 that 
although several pathogen targets do lack human orthologues, there are a number of 
proteins that are also present in humans or other mammals. If the ribosome is 
considered, the number of pathogen targets with human orthologues increases even 
further. Dihydrofolate reductase (DHFR) inhibitors, for example, are used as 
antibacterial agents, antineoplastic agents and antiparasitic agents in humans. 
Antibacterial DHFR-targeted agents, such as trimethoprim, generally achieve 
sufficient selectivity and therapeutic index over the human systems to avoid 
mechanism-based toxicity. 
Cancer drivers and cancer targets 
A substantial proportion of drug discovery efforts in the past decade have involved 
the rational selection of mechanistic cancer drivers to be targeted37. Moreover, 
cancer is the area of biggest growth in large-scale systematic efforts to identify 
disease drivers, powered by major international consortia38,39,40,41, and so it is 
interesting to consider the impact of such efforts on the identification of novel 
clinically validated targets. The 154 cancer drugs approved by the FDA can be 
broadly divided into the three groups mentioned above: 26 drugs are cytotoxic 
agents; 38 drugs are broadly cytotoxic and act at least partially through protein 
targets, such as proteasome inhibitors; and 85 drugs can be assigned to clear 
mechanistic protein targets. A further 5 drugs act through unknown or non-protein 
targets. Systematic efforts to identify cancer drivers based on 'omics' data have 
contributed considerably to the growth in the number of drugs in the third category in 
recent years. The impact of such approaches is clearly illustrated by the discovery in 
2002 of BRAF as the major driver for malignant melanoma, which led to the approval 
in 2011 of the BRAF inhibitor vemurafenib as the first targeted therapy for 
melanoma. Subsequently, the MEK inhibitor trametinib, which targets the same 
signalling pathway as vemurafenib, was approved in 2013. Another example is the 
discovery of EML4–ALK driver translocation in non-small-cell lung cancer42, leading 
to the approval of the ALK inhibitor crizotinib in 2011. 
The relationship between drug mechanisms and bona fide cancer drivers merits 
consideration. We have previously analysed the trends in identifying cancer drivers 
and have shown that multiple studies are converging towards ∼600 cancer drivers 
across different cancers43. We compared the lists of consensus 553 cancer 
drivers43 to the list of 109 protein targets of the 85 protein-targeted cancer drugs 
described above (Fig. 6) and found a small overlap (30 proteins) between the two 
sets. There are several reasons for this small overlap. Despite the large numbers of 
patients involved in these studies, they can be biased in their composition and in the 
statistical methodologies used to select drivers; hence, a gene may fall short of the 
final statistical prevalence cut-off. Another reason is that many of these drivers are 
newly discovered cancer-associated genes for which there has been little historical 
biological investigation; thus, time will tell whether they can yield useful targets for 
drug discovery. Indeed, our own analysis indicated that at least 10% of cancer 
drivers are likely to be druggable by small-molecule drugs, but such investigations 
had not been reported in the medicinal chemistry literature43,44,45. Finally, and 
importantly, non-oncogene addiction has been — and will remain — a key aspect of 
cancer that can be therapeutically targeted46,47. This trend is exemplified by FDA-
approved hormone-recognition- and hormone-biosynthesis-targeting agents such as 
aromatase inhibitors for breast cancer, cytochrome P450 family 17 subfamily A 
member 1 (CYP17A1) inhibitors for prostate cancer, and poly(ADP-ribose) 
polymerase (PARP) inhibitors for ovarian cancer. Agents under clinical investigation 
exploiting synthetic lethality to oncogenes include PARP inhibitors in DNA damage 
repair-deficient prostate cancer48. Other agents are exploiting non-oncogene 
addiction; for example, VLX-1570 inhibits proteasome 19s-associated protein 
ubiquitin-specific peptidase 14 (USP14) to exploit 19s addiction in multiple 
myeloma49. Furthermore, many cancer genes are loss-of-function drivers; in such 
cases, the gene has been deleted or disabled through the genomic aberration, and 
targeting these genes will typically require a synthetic lethality approach. Thus, 
systematic mapping of disease drivers can indicate future therapeutic strategies both 
by identifying potential targets and by highlighting key pathways that can be 
drugged. 
Concluding thoughts and future work 
In this article, we have provided an enhanced and updated perspective on the 
current diversity of approved drugs and their targets, with a focus on the trends and 
changes over the past 10 years7. Compiling an accurate and agreed list of drug 
efficacy targets is not a trivial task, and with work from three teams we have made 
significant progress towards this goal, as well as highlighted some of the practical 
challenges. These challenges include resolving the non-trivial relationship between a 
gene and a drug target, assigning the target, and finally establishing a convention to 
deal with complexes, subunits and splice variants and protein isoforms when 
counting final effective molecular targets — a major factor in the increase in the 
number of protein targets to 667 from the 324 identified in our previous study7. All of 
this is a prerequisite for analysing the diversity of existing drugs and targets in the 
light of their disease coverage. However, as the literature changes continuously in 
terms of the knowledge available about the mechanisms of action of drugs, these 
annotations will need to be updated frequently. Consequently, this data set will be 
maintained and made publicly accessible. A subset of the merged drug efficacy 
target data (referred to as Tclin) is currently available on the Illuminating the 
Druggable Genome website; see Further information). 
Interestingly, in the 10 years since the publication of our previous enumeration of 
drug targets, privileged families such as rhodopsin-like GPCRs, nuclear receptors 
and VGICs have largely maintained their dominance of the drug target space, 
underlining the continuous utility of protein families endowed with druggable binding 
sites. The major changes over the past decade are in the proportion of protein 
kinase and protease targets; together these previously made up <2% of the total 
target set, and now represent 6% (protein kinases) and 4% (proteases) of all targets 
of approved drugs. Reassuringly, the long tail of single exemplar targets from several 
underrepresented families continues to grow, indicating our ability to innovate in drug 
discovery. 
It is interesting to speculate on the relative contribution of phenotypic versus targeted 
screens to the discovery of first-in-class drugs50,51. The simplest view would be that 
small-molecule drugs for which polypharmacology is required for their action, such 
as sunitinib, are more likely to have been discovered through phenotypic rather than 
targeted screens. However, the data may indicate the opposite. Because phenotypic 
screens are often optimized against mechanistic and pharmacodynamic biomarker 
modulation, there is pressure towards more specific pharmacology of drugs 
discovered in this way. By contrast, discovering a small-molecule drug through a 
target-based screen optimizes the activity of the drug against the desired target, and 
selectivity against a few identified off-targets, without properly investigating the 
broader cellular activity of the agent. 
As data on tissue expression and causal models mapping molecular to clinical 
events continue to emerge, the relationship between drug efficacy targets and the 
tissue localization of disease will progressively be accounted for, because drug 
action is more likely to be exerted in the tissue of choice. For example, although the 
anti-Parkinsonian drug ropinirole is more potent at the D3 receptor than the D2 
receptor by an order of magnitude, we annotate the D2 receptor as the mechanism 
of action target because D2 receptors, but not D3 receptors, are expressed in the 
substantia nigra, the pathologically relevant tissue for anti-Parkinsonian drugs (see 
Further information). Future efficacy target annotations are anticipated to make 
extensive use of unambiguous tissue colocalization data for both target and disease. 
As our understanding of the causes of complex disease deepens, we find that such 
diseases involve a combination of environmental factors, genetic and epigenetic 
dysfunction. Thus, will a reductionist approach to targeted therapy still have a role in 
the future? Regardless of the initial cause, most human disease is either initiated or 
mediated by the aberrant action of proteins. Hence, an armoury of mechanistically 
sophisticated and thoroughly experimentally annotated drugs that target this 
complexity is required, including incorporation of drug combinations52, network 
drugs53 and polypharmacology54. These approaches are of particular importance in 
cancer and infectious disease, for which heterogeneity and evolution under the 
selective pressure of standard-of-care drugs results in the emergence of drug 
resistance. 
Medical care has two goals: to properly diagnose the disease and to select the 
appropriate therapeutic. As long as (drug-induced) phenotypic alterations are 
observed under appropriate conditions, it is possible to steer medical care and adjust 
the therapeutic management for a better outcome. Hence, the key to successful drug 
discovery and application resides in the seamless integration of pathological 
mechanisms of disease (that is, molecular and cellular level processes) with 
diagnoses (clinical embodiments of disease at the organ and/or organism level) and 
therapeutics (that is, modulating clinical manifestations at the molecular level via 
therapeutics). 
Drug discovery and targeting remains a complex, costly and at times unpredictable 
process. However, used alongside the new insights into disease and fundamental 
biology that are emerging, we hope that knowledge about the associations between 
currently successful drugs, their efficacy targets, phenotypic effects and disease 
indications that we have reported here can help to contribute to the efficient 
discovery of a new generation of medicines. 
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Figure 1: Major protein families as drug targets. 
a | Distribution of human drug targets by gene family (left) and distribution by the 
fraction of drugs targeting those families (right); the historical dominance of four 
families is clear. b | Clinical success of privileged protein family classes. Distribution 
of non-approved compounds in ChEMBL 20 (extracted from the medicinal chemistry 
literature, with bioactivity tested against human protein targets) per family class, and 
distribution of approved drugs (small molecules and biologics) per human protein 
family class. 7TM, seven transmembrane family; GPCR, G protein-coupled receptor; 
LGIC, ligand-gated ion channel; NTPase, nucleoside triphosphatase; VGIC, voltage-
gated ion channel. 
 
  
Figure 2: Innovation patterns in therapeutic areas. 
Each node in the inner ring corresponds to a drug represented by its WHO 
Anatomical Therapeutic Chemical Classification System code (ATC code) or codes 
(see Further information). The inner ring corresponds to the level 1 of the ATC code 
(Table 2) scaled to the number of drugs in that category. The outer ring represents 
the level 3 of the ATC code. Each of the subsequent histograms illustrates the 
number of drugs (small molecules and biologics) distributed per year of first approval 
per level 3 of the ATC code. Maximum histogram scale: 100. The approval year 
refers to the first known worldwide approval date, if available, otherwise the first US 
FDA approval date. 
 
  
Figure 3: Innovation patterns in privileged protein classes. 
Bar chart depicting the number of drugs (small molecules and biologics) that 
modulate four privileged families, distributed per year of first approval. The total 
number of approved drugs is shown on top of each bar in bold font, together with the 
number and percentage of drugs approved since 2011 with respect to the total 
number of drugs modulating these four families. A spreadsheet view of these data is 
provided in Supplementary information S6 (table). “Ion channel” includes both 
voltage-gated and ligand-gated ion channels. Drugs without an ATC code 
(unclassified (U)) were excluded from this analysis. 7TM1, seven transmembrane 
family 1; GPCR, G protein- coupled receptor. 
 
  
Figure 4: Promiscuity of privileged protein family classes. 
Each node in the outer ring corresponds to a drug represented by its WHO 
Anatomical Therapeutic Chemical Classification System code (ATC code) or codes 
(see Further information). The outer ring corresponds to level 1 of the ATC code 
(Table 2) scaled to the number of drugs in that category. The inner ring represents 
level 2 of the ATC code. A node is connected to another when two drugs have an 
efficacy target that belongs to the same target class. a | Footprint of privileged family 
classes modulated by organic small-molecule drugs across disease. b | Footprint of 
privileged family classes modulated by biologic drugs across disease. Drugs without 
an ATC code (unclassified (U)) were excluded from this analysis. 
  
Figure 5: Protein efficacy targets availability across several model organisms. 
Each node in the outer ring corresponds to a drug represented by its WHO 
Anatomical Therapeutic Chemical Classification System code (ATC code) or codes 
(see Further information). The outer ring corresponds to level 1 of the ATC code 
(Table 2), scaled to the number of drugs in that category. The next ring represents 
level 4 of the ATC code. Each of the subsequent rings represents a different species, 
as indicated in the legend, and each section of the ring is coloured according to the 
presence or absence of orthologues of the efficacy targets of the drugs in that ATC 
level 4 category. The dark blue sections indicate the species of the protein efficacy 
targets. An expanded portion of the chart is shown at the bottom of the figure, and an 
expandable version of the full chart is provided in Supplementary information S5 
(figure). 
  
Figure 6: Overlap of cancer drug targets with cancer drivers. 
We grouped the cancer drugs approved by the US FDA into three categories: 
broadly cytotoxic agents, such as platinum complexes and DNA intercalating agents; 
cytotoxic agents that act through a protein, such as tubulin inhibitors that do not have 
biological selectivity for cancer cells; and targeted agents that act through clear 
protein function-modulating mechanisms, such as kinase inhibitors and nuclear 
hormone receptor antagonists. When we compared the targets of agents in the third 
group to a consensus reference list on cancer driver genes43, we observed only a 
small overlap between cancer drivers and current cancer drug targets. 
 
